Wearable startup CUDIS launched a smart ring with an AI coach that rewards users with redeemable points for healthy habits, part of a wider push to gamify wellness tracking and boost engagement.
GSK licensed a cellular-biology foundation model from UK biotech Relation Therapeutics in a deal worth up to $110 million, part of a wider pharma shift toward licensing specialized AI platforms.
Zealand Pharma struck a deal worth up to $1.2 billion with AI protein-design company Generate Biomedicines to pursue new obesity treatments, joining a wave of major AI drug discovery partnerships.
Big pharma has committed billions to AI drug discovery deals, but no AI-designed drug has yet reached the market, leaving a growing gap between investment enthusiasm and proven clinical payoff.
India's MeitY Secretary said AI can expand healthcare accessibility and improve diagnosis nationwide, comments reflecting the government's growing emphasis on AI as a tool to address the country's rural doctor shortage.
Utah launched a pilot allowing patients to receive AI-generated prescriptions for topical acne medication without an in-person visit, even as the state's medical board separately moves to suspend a different AI prescribing program over safety concerns.
Mass General Brigham's new AI intake agent inside MyChart routes primary-care patients to appointments, with the health system reporting 77% of users get seen the same day they report a new concern.
Northwestern Medicine embedded OpenEvidence's AI clinical guidance directly into its Epic electronic health record, letting physicians check dosing and treatment guidelines without leaving the patient chart.
AstraZeneca signed a deal worth up to $1.5 billion with AI drug discovery startup insitro targeting liver and heart disease, paying just $40 million upfront with the rest tied to development milestones.
Heidi Health has launched Heidi II, adding AI agents that handle administrative tasks around patient visits while the company insists clinicians retain final approval over decisions.